Algen Biotechnologies

Algen Biotechnologies is a San Francisco-based biotechnology company that integrates proprietary CRISPR gene-modulation technology with artificial intelligence to accelerate drug discovery. Its core platform, AlgenBrain, utilizes deep learning models to process large-scale, single-cell gene expression data, enabling the company to reverse-engineer disease trajectories and identify causal RNA signaling pathways. By fine-tuning gene modulation, the company generates high-resolution maps of cellular states, which allows researchers to uncover novel, high-confidence therapeutic targets and develop precise interventions for complex, progressive diseases. The platform is designed to be disease-agnostic, providing a foundation for drug development across various therapeutic areas including oncology, immunology, and metabolic disorders.

This technology-driven approach aims to improve the translatability of preclinical discoveries from the laboratory to the clinic, addressing critical challenges in current drug discovery, such as the lack of clinically relevant endpoints and the tendency of existing models to rely on correlation rather than biological causality. Algen Biotechnologies focuses on finding transformative medicines with minimal toxicity, backed by a preclinical pipeline that includes multiple internal development programs. The company has demonstrated its technical and commercial viability through strategic industry engagement, notably entering a significant multi-target partnership with AstraZeneca to advance AI-powered drug discovery for immunological diseases, and by building a collaborative research environment involving experts in CRISPR and data science.